Iovance Biotherapeutics Appoints Friedrich Graf Finckenstein, M.D., as Chief Medical Officer
July 18, 2019 08:00 ET
|
Iovance Biotherapeutics, Inc.
SAN CARLOS, Calif., July 18, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on...
Iovance Biotherapeutics Provides Cervical Cancer Program Updates Following End of Phase 2 Meeting with U.S. Food and Drug Administration (FDA)
July 02, 2019 07:30 ET
|
Iovance Biotherapeutics, Inc.
FDA agreed that the ongoing single-arm Phase 2 innovaTIL-04 study may be sufficient to support registration of LN-145 in advanced cervical cancer SAN CARLOS, Calif., July 02, 2019 (GLOBE NEWSWIRE)...
Iovance Biotherapeutics Appoints Athena Countouriotis, M.D., to Board of Directors
June 11, 2019 07:00 ET
|
Iovance Biotherapeutics, Inc.
SAN CARLOS, Calif., June 11, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on...
Updated Results of Studies in Advanced Cervical Cancer and Melanoma Support Long-Term Efficacy of Iovance Tumor Infiltrating Lymphocyte (TIL) Therapy
May 31, 2019 07:00 ET
|
Iovance Biotherapeutics, Inc.
Complete Response rate of 11 percent observed in the LN-145 study in cervical cancer Median duration of response has not been reached at 7.4 month median follow-up in the ongoing study of LN-145 in...
Iovance Biotherapeutics to Participate in Upcoming Conferences in June
May 31, 2019 06:59 ET
|
Iovance Biotherapeutics, Inc.
SAN CARLOS, Calif., May 31, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on...
Iovance Biotherapeutics Announces New Facility to Support U.S. Production of Tumor Infiltrating Lymphocyte Cell Therapy Products
May 29, 2019 08:00 ET
|
Iovance Biotherapeutics, Inc.
SAN CARLOS, Calif., May 29, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on...
Iovance Biotherapeutics Announces Breakthrough Therapy Designation for LN-145 for Treatment of Advanced Cervical Cancer Patients Who Have Progressed on or After Chemotherapy
May 22, 2019 16:30 ET
|
Iovance Biotherapeutics, Inc.
SAN CARLOS, Calif., May 22, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on...
Iovance Biotherapeutics Announces Updates to Tumor Infiltrating Lymphocyte (TIL) Therapy Clinical Programs
May 15, 2019 17:27 ET
|
Iovance Biotherapeutics, Inc.
Patients with advanced cervical cancer treated with LN-145 had an objective response rate of 44 percent Patients in Cohort 2 with advanced melanoma treated with lifileucel following failure of...
Iovance Biotherapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update
May 07, 2019 16:01 ET
|
Iovance Biotherapeutics, Inc.
- First patient dosed in pivotal Cohort 4 in study of lifileucel in advanced melanoma; regulatory submission planned for late 2020 - - New interim data from melanoma Cohort 2 and cervical...
Iovance Biotherapeutics to Participate in Upcoming Conferences in May
May 02, 2019 07:00 ET
|
Iovance Biotherapeutics, Inc.
SAN CARLOS, Calif., May 02, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on...